Combining PARP Inhibitor with Immunotherapy - Does the Promise of Preclinical Data Translate to Clinic? The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. shivaani kummar ohsu email - sosfoams.com OHSU Knight Cancer Institute is a national leader in cancer research and training and well-known for its ability to turn cancer research discoveries into new cancer treatments. Kummars remarkable accomplishments, combined with her ability to connect with people and her clear vision for how to grow the hematology-oncology division, made her our top candidate. And to train and inspire the next generation of doctors and scientists. 11 Jun 2022. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Uncategorized . Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. Today is a global celebration of giving an opportunity to support the causes that matter the most to you. Shivaani Kummar, MBBS is an Oncologist. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU OHSU Knight Cancer Institute Archives - The Cancer Letter You may also qualify for Phase 1 Program trials. Verified email at ohsu.edu. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. What is the importance of philanthropy to your work? The couple says their ultimate goal is to develop new effective therapies for cancer. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. [] , 'Nm301' Als Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. shivaani kummar ohsu email - chinamanpavers.in The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP Support the Abortion Care and Training Fund. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . (44 Ratings, , 'Bal0891' 1 Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . The units team of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Dr. Shivaani Kummar, MD | Palo Alto, CA | Oncologist | US News Doctors These topic labels come from the works of this person. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. shivaani kummar ohsu email. Shivaani Kummar. Expanding access to experimental cancer - Cancer Translated . Claire Yoshida, M.S.N., A.C.N.S.-B.C., A.C.H.P.N. By continuing you agree to the use of cookies. Dive into details by clicking on the dots or, Knight Cancer Translational Oncology Program, Calculated based on number of publications stored in Pure and citations from Scopus, PQ3: Age-related immune deviation and cancer outcome, [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors, Understanding the origins of rapid recurrence of pancreatic cancer after resection. You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number - 503-314-7168). Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Administrative Coordinator, Felicia Feingersch The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. 2001-2022 Oregon Health & Science University. OHSU is an equal opportunity affirmative action institution. Harnessing the predictive power of preclinical models for oncology drug Shivaani Kummar - .. - Oregon Health & Science University - ZoomInfo If you made any changes in Pure these will be visible here soon. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. shivaani kummar ohsu email - howfenalcooksthat.com Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU middlesex county community college nursing program nj Email: trials@ohsu.edu Call: 503-494-1080 Oregon Health & Science University. Our ability to move these projects forward and to take on new projects is limited by the available resources. Dr. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Program Guide - ASCO Meeting Program Guide - American Society of Notice of Privacy Practices She also leads the division of hematology & medical oncology in the OHSU School of Medicine. what was bolivar's ultimate goal? This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. Their mission is clear: To give patients excellent care. (OHSU/Joe Rojas-Burke), The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Nature reviews Drug discovery 9 (11), 843-856. (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Knight Cancer Institute | OHSU Knight Cancer Institute | OHSU Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Dr. Drukers approach to team science is incorporated throughout the institutes infrastructure. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. Stat4Onc Annual Symposium (2022) - University Of Connecticut Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . Knight Cancer Institute Leaders | Knight Cancer Institute | OHSU However, high costs, long development t February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC Tom Sellers named lead research officer at OHSU Knight Cancer Institute Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . OHSU expands capacity for cancer clinical trials | OHSU News CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. Shivaani Kummar, MBBS, Portland, OR | Oncologist 12 Reviews). They say they shared an interest in cancer drug discovery and development that grew after their marriage. NPI 1053612341 Dr. Shivaani Kummar in Portland - Address, Medicare Administrative Coordinator, Ingrid Studebaker We have a billion reasons why you should join us. OHSU Foundation P.O. S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. Recent external collaboration on country/territory level. Dr. Shivaani Kummar is an oncologist practicing in Bethesda, MD. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Accepting new patients The new early-phase research unit completes this expansion in the building. BYLINE. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . Shivaani Kummar. Keep me signed in. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. . Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. Hung, M.D. In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Give Now. In 2021, we held our 4th Stat4Onc Symposium virtually by Stanford University. Dr. Shivaani Kummar - Medical Oncology, Portland OR shivaani kummar ohsu email MSK earns merit extension from NCI - The Cancer Letter February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC People | OHSU Administrative Coordinator, Denise Hopkins Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. 9842741222, 9942641222, 9842724434 chinamanpaversscc@gmail.com. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. Dr. Jody Kujovich, MD - Portland, OR | Oncology - Doximity Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? General Information Email: ohsufinfo@ohsu.edu, Mailing Address Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. shivaani kummar ohsu email. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar - Professor of Medicine - Stanford - LinkedIn Equipment. condition, procedure, doctor name. Read More Contact Shivaani Kummar's Phone Number and Email Last Update 11/29/2022 2:55 AM Email s***@ohsu.edu Engage via Email Contact Number (***) ***-**** Engage via Phone Mobile Number (***) ***-**** Engage via Mobile HQ Phone Lisa M. Coussens, M.D. Title. (h.c.), Ph.D., FAACR. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Sort by citations Sort by year Sort by title. Her research interests focus on developing novel therapies for cancer. Password. scripps institution of oceanography graduate programs; rosemont seneca advisors website She accepts multiple insurance plans. Shivaani Kummar - PMWC Precision Medicine World Conference Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. 2001-2023 OHSU. Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Press Release: Husband-Wife Team From Stanford - The Lund Report 2001-2023 OHSU. Want to join the faculty at the Knight Cancer Institute? The field of oncology is so broad, and theres so much to be done, Kummar says. , Bal0891 1 Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. For help with all referral needs and questions, visit Referring Physicians. Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. Dive into the research topics where Shivaani Kummar is active. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. Shivaani Kummar: STUDY00021766: . (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. To find better ways to treat patients. We are thrilled he is able to co-lead this new venture. February 17, 2023. Notice of Privacy Practices Clinical Activity of the -Secretase Inhibitor PF-03084014 in Adults Why are early phase clinical trials important for advancing the care of people with cancer? By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. massachusetts vs washington state. Where is Dr. Shivaani Kummar located? (OHSU/Kristyna Wentz-Graff). A Novel Artificial Intelligence-Powered Method for Prediction of Early We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD This philanthropy-fueled research revolution is already saving lives. The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. SHIVAANI KUMMAR, Medical Oncology PORTLAND, OR - NPI 1053612341 What sort of projects are you working on right now? OHSU is an equal opportunity affirmative action institution. What excites you about coming to work in the morning? Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? Shivaani Kummar M.D., FACP | Health care provider | OHSU Increasing (gender) diversity on a journal: a case study - Elsevier Connect Together their goal is to find a cure for cancer. Overall: 4.7 out of 5 . Faculty and staff recruitment information. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734.